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Objectives: There is inconsistent evidence about the association between inflammatory 
disorders with depression and anxiety onset in a primary care context. The study aimed 
evaluate the risk of depression and anxiety within multisystem and organ-specific 
inflammatory disorders. 
Methods: Prospective cohort study with primary care patients from the UK Clinical Practice 
Research Datalink diagnosed with an inflammatory disorder between 1st of January 2001 and 
31st of December 2016. These patients were matched on age, gender, practice, and index date 
with patients without an inflammatory disorder. The study exposures were seven chronic 
inflammatory disorders. Clinical diagnosis of depression and anxiety represented the outcome 
measures of interest.  
Results: Among 538,707 participants, the incidence of depression ranged from 14 per 1000 
person-years (severe psoriasis) to 9 per 1000 person-years (systemic vasculitis), substantively 
higher compared to their comparison group (5 to 7 per 1000 person-years). Hazard ratios 
(HR) of multiple depression and anxiety events were 16% higher within inflammatory 
disorders (HR, 1.16, 95%CI 1.12-1.21, p<0.001) compared to the matched comparison group. 
The incidence of depression and anxiety was strongly associated with the age at 
inflammatory disorder onset. The overall HR estimate for depression was 1.90 (95%CI, 1.66-
2.17, p<0.001) within early onset disorder (<40 years of age) and 0.93 (95%CI, 0.90-1.09, 
p=0.80) within late-onset of disorder (≥60 years of age).  
Conclusions: Primary care patients with inflammatory disorders have elevated rates of 
depression and anxiety incidence, particularly those patients with early onset inflammatory 
disorders. This finding may reflect the impact of the underlying disease on patients’ quality 
of life, although the precise mechanisms requires further investigation. 
Keywords: Autoimmune diseases, Epidemiology, Inflammation, Mental Health, 
Primary care  
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Key messages 
What is already known on this subject? 
- Several cross-sectional studies suggested but did not establish a contributory role 
of inflammation in the initiation of depression and anxiety within patients 
diagnosed with chronic inflammatory disorders. 
What does this study add? 
-  In a prospective cohort study with 538,707 patients from primary care, a 
significant increment in the onset of new of depression and anxiety events was 
documented within organ-specific and multisystemic inflammatory disorders.  
- The incidence of depression or anxiety varied with the age at inflammatory 
disorder onset. 
How might this impact on clinical practice or future developments?  
- The elevated risk of depression and anxiety means clinicians should be vigilant for 
early symptoms of depressive or anxiety in this highly at-risk group of patients. 
-  The risk was greater among patients with younger age at inflammatory disorder 
onset, supporting tailored preventative approaches early in the course of a chronic 
disorder.   
- The study, however, does not demonstrate a causal relationship between 
inflammation with depression and anxiety. 
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Introduction 
A growing body of evidence indicated that low-grade inflammation may play an influential 
role in the onset of depression and anxiety.1 Past research has linked upregulated pro-
inflammatory cytokines and increased levels of acute-phase reactants with changes in 
neurotransmitter and neuroendocrine functioning related to psychiatric disorders.2 3 This 
evidence supports a link between depression and anxiety with inflammatory disorders (e.g. 
rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis (AS)), and cross-sectional studies 
are in line with this suggestion. 4-7 Evidence from prospective studies exploring the role of  
inflammatory disorders in  depression and anxiety onset were, however, inconsistent.8 9 Little 
is known about the incidence of depression or anxiety across clinically diverse inflammatory 
disorders. Differences in genetic influences and treatment choices across inflammatory 
disorders may lead to variation in depression or anxiety onset.10 11 The genetic association 
with human leukocyte antigen (HLA) alleles, for instance, was stronger within AS compared 
to RA.10 Quantifying the extent to which the link between inflammatory disorders with 
depression vary by individual disorders may suggest mechanisms underlying specific 
relationships and ultimately facilitate targeted preventative approaches. There is substantive 
variation in the age of onset across individual inflammatory disorders that may also lead to 
differential association with depression or anxiety,12 13 in turn more prevalent in early adult 
years. The incidence of depression or anxiety, thus, may be lower across disorders with late 
age at onset (e.g. RA) than those with early age at onset (e.g. Crohn’s disease). The detection 
of disparities in mental health burden could guide treatment choice and effective tailoring of 
healthcare resources. The aim of the present study was to implement a prospective cohort 
study within a large primary care database to test the hypothesis that the incidences of 
depression or anxiety varied across specific inflammatory disorders. It was also hypothesised 
that depression or anxiety risk was greatest within people with an early age at disorder onset.   
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Methods 
Data 
A prospective matched cohort study design was implemented in the Clinical Practice 
Research Datalink (CPRD), among the world largest electronic medical records database. 
CPRD collects routine primary care data on over 14 million patients (≈6.7 million active) 
from around 675 practices throughout the UK National Health Service (NHS). All patients in 
the NHS are registered with a general practice that provides all their primary care and 
coordinates secondary and community care. Important diagnostic and therapy information 
from referrals to secondary or community care services are captured by primary care records. 
Patients included in the CPRD are broadly representative of the UK’s wider population in 
terms of age, gender, and ethnicity.14 The validity and accuracy of CPRD diagnostic and 
prescription data have been demonstrated across a wide range of disorders including cancer,15 
stroke,16 COPD,17 depression and anxiety,18 rheumatoid arthritis,19 inflammatory bowel 
disorders,20 and autoimmune disorders.21 22  
 
 Study population 
A cohort of primary care patients aged >18 years with a first-ever diagnosis of a chronic 
inflammatory disorder (psoriasis, Crohn’s disease (CD) and ulcerative colitis (UC), RA, SLE, 
ankylosing spondylitis (AS), and systemic vasculitis (SV)) recorded between 1st of January 
2001 and 30th of September 2016, who were depression or anxiety disorders free at the time 
of inflammatory disorder diagnosis were sampled from the CPRD. The date of diagnosis was 
defined as the index date. The index date for patients transferring into the practice was their 
practice registration date and the practice up-to-standard (UTS) date was used if a practice 
joined the data base during the recruitment period. The end of recruitment was the earliest of 
30th of September 2016 or the death date or transferred out of the practice date. Patients 
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below the age of 18 at the time of diagnosis were excluded from the study sample because the 
presentation and course of inflammatory disorders might be different in younger people.23  
All diagnoses were derived from the medical codes recorded by family physicians in 
patients’ electronic health records. These patients were matched (a 1:2 ratio of inflammatory 
exposed to 2 matched non-exposed) on age (year of birth), gender, practice, and index date 
with a group of patients without a chronic inflammatory disorder selected for this study 
during the recruitment period. Matched controls were assigned the index date of the 
inflammatory disorder diagnosis of the matched case. Similar to the inflammatory patients, 
matched controls with a diagnosis of depression or anxiety before the assigned index date 
were excluded from the analyses.  Psoriasis patients are commonly classified into severe if 
they were prescribed a systemic therapy (i.e. methotrexate, azathioprine, cyclosporine, 
hydroxyurea) or phototherapy (psoralen and ultraviolet A) during the study period, or into 
mild psoriasis if no such treatment was recorded.24 25 This classification has been validated 
with similar databases26-28 and has also been used in this study. Data were extracted from the 
CPRD in September 2017.  
 
Outcome 
The study primary outcome measures were a new Read medical code for a diagnosis of 
depression or anxiety used as binary variables (yes/no).29 The date of the first outcome code 
following an inflammatory disorder diagnosis was referred to as the outcome index date. 
Depression was broadly defined to include single episode of depression, recurrent depression 
events, and bipolar depressive events to allow for the possibility that chronic inflammation is 
implicated across the wider spectrum of the depressive disorder. In keeping with other 
studies,30 anxiety was broadly defined to include generalised anxiety disorders, phobias, 
panic attacks, and panic disorders.  
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Covariates 
Factors known to be associated with chronic inflammation and depression or anxiety were 
adjusted for in the analyses. These covariates included age (continuous), gender (male vs 
female), body mass index (<18.5, 18.5 to 25, >25 to <30, 30 to <35, and ≥35 kg/m2), index of 
multiple deprivation (quintiles) , blood pressure (BP) (<120 mmHG, normal; 120-139 
mmHg, borderline; ≥140 mmHg, hypertension), smoking (ex- or current vs never), drinking 
(ex- or current vs never), physical comorbidities (yes/no) (i.e. cancer, diabetes, stroke, 
coronary heart disease (CHD), dementia, epilepsy, chronic obstructive pulmonary disease 
(COPD), liver disorders, kidney disorders, insomnia), stressful life events (e.g. stress at home 
or at work), together with prescription of statins, antihypertensive, anti-diabetic, and 
hypnotics. Previous studies31 32 linked corticosteroids and non-steroidal anti-inflammatory 
drugs (NSAIDs) with increased risk of depression and were therefore also included as 
covariates. For each potential confounder the value closer to the index date and within the 
five years period prior to a chronic inflammation diagnosis was included. For instance, if a 
patient had two BP measures within 5 years prior to the baseline (e.g. at 4 years and at 2 
years prior to baseline), the value closer to the study baseline (e.g. at 2 years) was included in 
the analyses. Expanding the baseline period to available data was found to enhance covariate 
sensitivity by capturing data that would otherwise be missed.33     
 
Statistical analysis 
The analyses were conducted in a time-to-event framework. Failure was classed as a new 
diagnosis of depression or anxiety. Participants contributed person-time to the analysis from 
the study start date (the later of the start of the participant’s record in CPRD or the diagnosis 
date for a chronic inflammatory condition). Follow-up ended at the earliest of the study 
outcome date, the end of a participant’s registration, the last date of CPRD data collection, or 
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date of death. All participants had at least 12 months of follow-up recorded had at least one 
medical event recorded from the study start date to the study end date.  
A Cox proportional-hazards model for clustered data based on the matched pairs was 
implemented with the use of a multiple-failure events to allow for the possibility that each 
patient may experience more than one outcome event.34 This approach permits analysis of 
data for each of multiple outcomes in a single model, allowing the most efficient use of each 
patient’s data and reducing problems of multiple testing.24 The multiple-failure model avoids 
the need to censor records at earlier outcome events or to test hypotheses separately for each 
outcome. Robust variance estimator was used to adjust for the dependency introduced by the 
matching variables. This approach is considered35 superior to matched stratification as it 
allows for unbiased estimation of hazard ratios. Because confounding by matching variables 
cannot be excluded,36 the estimation models adjusted for: matching variables (age, gender, 
practice, index year) and all study covariates listed above. A similar estimation was 
performed to estimate whether depression or anxiety onset varied with the age (<40, 40-49, 
50-59, and 60 or over) at inflammatory disorder diagnosis. Additional analyses estimated the 
specific associations between each inflammatory condition with depression and anxiety in 
separate Cox regression models with robust estimate variance. The analyses used the Efron 
method to handle tied events. Forest plots were used to present measures of association for 
age subgroups and individual inflammatory disorder. A random-effects meta-analysis was 
implemented to evaluate heterogeneity by chronic inflammatory disorder and overall.37 The 
proportionality assumption was tested and confirmed using Schoenfeld residuals. As this was 
an exploratory study no adjustment for multiple comparisons was made, and therefore 
marginally significant results may be type I errors. Several sensitivity analyses were 
conducted. Firstly, alternative follow-up times were used by starting the follow-up 
immediately after the inflammatory disorder diagnosis.  Secondly, depression and anxiety 
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were redefined to include both a clinical diagnosis code plus a relevant prescription (i.e. 
antidepressant or anxiolytic drugs, respectively). Thirdly, stratification by matched pairs was 
implemented to account for the matching. Fourthly, to test the robustness of psoriasis 
findings, data on systemic therapy were used to classify RA and systemic vasculitis patients 
(the only sufficiently powered disorders) into mild (no systemic therapy) and severe 
(systemic therapy). The effect of competing risk on mortality was also assessed. Multiple 
imputation by chained equation was used to handle missing data. The analyses were 
implemented using Stata version 15.   
 
Results 
The analyses included 180163 patients with chronic inflammatory disorders (see Table 1) that 
were individually matched for age, gender, practice, and index date with 358544 control 
patients without a diagnosis of chronic inflammation. The median duration of follow-up was 
around 4 years for patients and controls. While clinical diagnosis and therapy data were 
comprehensive, among lifestyle factors missing information ranged from around 6% for 
smoking to 22% for alcohol status. Selective baseline characteristics of study participants are 
described in Table 1 (See Table S1 in Supplementary material for full data description).  
 
Insert Table 1 about here 
 
Figure 1 shows the across all inflammatory disorders, the incidence of both depression or 
anxiety was greater within cases compared to the matched controls. The highest incidence 
rate was observed within severe psoriasis (14 per 1000 person-years), followed by those 
diagnosed with CD and AS (12 per 1000 person-years). Similar trends emerged with regards 
to the incidence of anxiety (Figure S1 in the Supplement).  
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Insert Figure 1 about here 
 
Table 2 presents the results of the analyses by study outcomes indicating increased hazard 
rates of depression and anxiety across all chronic inflammatory disorders. The strongest 
association was observed for severe psoriasis, being associated with a 71% increased rate of 
new depression onset (hazard ratio (HR) 1.71; 95% confidence interval (CI), 1.52-1.93, p-
value<0.0001) compared to the matched comparisons. Regarding new anxiety onset, patients 
diagnosed with AS presented with the largest hazard rates (1.36, 1.23-1.51, p<0.0001) 
compared to their matched comparison group. Age-related analyses revealed higher 
depression and anxiety incidence among persons with early inflammatory disorder onset. 
Kaplan-Meier survival curves are presented in Figure S2, Supplementary material. 
 
Insert Table 2 about here 
 
Figure 2 displays the results from the multiple outcome models, with patients being allowed 
to experience either depression or anxiety in a random order. Compared to the matched 
group, patients with an inflammatory disorder experienced a 16% (1.16, 1.12-1.21, p<0.001) 
increased risk of depression or anxiety events. Patients diagnosed with CD presented with the 
highest hazard ratio (1.23, 1.13-1.33, p<0.001), while those with mild psoriasis with the 
lowest hazard ratio (1.08, 1.03-1.13, p<0.001). Age-based analyses (Figure 3) indicated that 
the pooled hazard rate for multiple depression or anxiety incidence was 1.71(1.59-1.84, 
p<0.001) among patients with early inflammatory disorder onset (<40 years of age), which 
declined to 0.93 (0.85-1.01, p=0.080) among those with late disorder onset (≥60 years) (See 
Figure S3 in the Supplement for findings among 40 to 49 and 50 to 59 years of age groups).    
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Insert Figure 2 about here 
Insert Figure 3 about here 
 
Sensitivity analyses 
Sensitivity analyses using a more stringent criteria for depression and anxiety definition (e.g. 
clinical diagnosis plus corresponding drug prescriptions) resulted in modestly higher 
estimates, validating the robustness of the main findings (Figure S4 and Table S1). Analyses 
stratified by matched pairs endorsed the estimates and associations of the study findings. 
Systemic therapy-based sensitivity analyses indicated that both severe RA (1.43,1.28-1.59, 
p<0.001) and systemic vasculitis (1.65,1.20-2.25, p<0.001) presented greater risk of 
depression incidence relative to mild RA (1.36, 1.25-1.49, p<0.01) or mild systemic 
vasculitis (1.42,1.27-1.60, p<0.001).  
 
Discussion 
The main aim of the present study was to provide a comprehensive understanding about the 
burden of common mental disorders across specific inflammatory disorders within a primary 
care context. Within a large prospective design, several clinically diverse inflammatory 
disorders presented with a consistently elevated risk of depression and anxiety incidence. In 
particular, a 16% overall increased risk of multiple depression and anxiety events emerged 
across seven specific chronic inflammatory disorders (RA, psoriasis, CD, UC, SLE, SV, and 
AS). Associations were observed between incident depression with each specific 
inflammatory disorder, although the effect size was of lower magnitude than suggested by 
findings based on secondary care-based populations.4 The reason for this discrepancy may be 
that  a smaller proportion of patients with inflammatory disorders, those with most severe or 
active disease, are seen in secondary care.38  In our study, the incidence of depression and 
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anxiety was higher for patients with severe psoriasis relative to those with mild psoriasis. 
This suggestion was substantiated in sensitivity analyses among RA and systemic vasculitis 
disorders.  
 
The pooled incidence of depression and anxiety was considerably increased (71% increment) 
among primary care patients with early onset inflammatory disorder (<40 years of age) and 
less so (-7%) among those with late disorder onset (≥60 years of age). Early onset 
inflammatory disorders are associated with more widespread inflammation, increased 
frequency of active disease, and more aggressive disease manifestation and treatment 
compared to late-onset disorder.39 Whether the increased incidence of depression or anxiety 
within early disorder onset was caused by increased disease activity or delay in disorder 
diagnosis and treatment (or their combined effect), needs further exploration.  
 
All seven chronic disorders analysed in this study are connected by common underlying 
inflammatory mechanism and the consistently elevated rates of depression and anxiety 
incidence across them might support a potential role of inflammation in the pathogenesis of 
these disorders, though this suggestion was not directly tested in this study. The main 
alternative hypothesis that cannot be excluded from this study design is that depression and 
anxiety may represent emotional responses to the experience of living with a distressing and 
often debilitating inflammatory disorder. The psychosocial and physical effects of the 
inflammatory disorder might therefore contribute to the onset of depressive and anxiety 
symptoms. For example, increased depression and anxiety incidence among primary care 
patients with early disorder onset, as found in this study, may reflect these patients presenting 
with more extensive and severe manifestations of the inflammatory disorder.40 The elevated 
rates of depression events among patients with severe psoriasis relative to those with mild 
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psoriasis seem to be in line with a disease response hypothesis. Pain, disfigurement, 
loneliness, and stigma associated with severe inflammatory disease indicators (e.g. eruptive 
psoriasis, multiple nail lesions), for example, could worsen patients’ sleep quality and prevent 
them from full social participation, leading to the onset of depressive symptoms.41 
 
The results of the present study raise important questions about the assessment and 
management of common mental health disorders among younger patients diagnosed with 
specific inflammatory disorders. Irrespective of whether psychological problems are the 
consequence of the emotional reaction to disease and disability or of a common inflammatory 
etiology, there seems a clear association between inflammatory disorders and depression or 
anxiety, especially for younger early-onset patients. Routine assessments of patients’ mental 
health could lead to improved prevention and treatment outcomes. If further research 
supports the common inflammatory etiology hypothesis, then clinical intervention might 
target the inflammatory response itself. Renewed interest in the potential effectiveness of 
immunomodulatory therapies (e.g. new biologics, methotrexate) for the prevention of 
treatment-resistant depression may indicate one way forward. 
 
Previous prospective studies explored the association between depression and anxiety with 
specific inflammatory disorders. 9 42 Marrie et al.,9 43 for example, documented somewhat 
higher incidence rates of depression and anxiety among patients with RA and IBD. Marie et 
al.’ studies did not adjust for differences in chronic illnesses (e.g. CVD, diabetes, CKD) at 
baseline, did not account for matching in their analyses, used a different case definition (e.g. 
exclusion of cases within a 5-year period from index date), and relied on a more local 
population. These variations may account for the observed differences in effect size between 
our and Marrie et al. findings. Meesters et al.44 also documented higher  incidence rates of 
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depression events among AS patients from primary care compared to our findings, possibly 
due to previous study failure to adjust for other covariates apart from age and gender. An 
earlier study found no increased risk of depression among patients diagnosed with CD or 
ulcerative colitis42: this may reflect previous study’ lack of a comparison group or shorter 
follow-up (<5 years). Recent studies6 27 indicated greater incidence of depression among 
patients diagnosed with severe psoriasis relative to those with mild psoriasis, as observed in 
this study. The decline in depression incidence with age at disorder onset is in line with an 
earlier systematic review among RA patients,4 and extends previous findings to anxiety.  
 
Strengths and limitations 
The present study has several strengths including nationally representative primary care 
population, prospective study design, and clinically valid diagnoses of inflammatory 
disorders, depression and anxiety. The inclusion of primary care patients with systemic and 
organ-specific inflammatory disorders, ensures the generalisability of the study findings to 
real-world clinical practice. While our data possibly contains all diagnoses issued within 
primary care, it may be less complete with regards to diagnoses made in secondary or 
community care.45 Nine out of ten adults with mental health disorders are supported in 
primary care in the UK, implying that only a small number of cases are not captured by the 
CPRD. The use of antidepressant and anxiolytics therapies as sensitivity analyses may have 
also mitigated against diagnostic bias, given that drug prescribing is often considered a 
reliable marker for case identification.46 Clinicians may be more alert (or ask different 
questions) to depressive or anxiety symptoms among patients with inflammatory disorders 
due to increased contact with the healthcare system, and thus more likely to identify relevant 
cases.  The mean number of primary care consultations, however, was similar between 
inflammatory patients and matched controls (data not shown). The precise timings of the 
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onset of exposure or outcome measures cannot be determined precisely in observational data, 
precluding robust causal inferences. To mitigate against this concern, the analyses excluded 
outcome measures that occurred during the first 12 months following an inflammatory 
disorder diagnosis. Our large study sample comprised a heterogeneous group of patients with 
distinctive underlying disease severity and symptomatology, potentially masking subgroups 
of patients that could present with clinically significant mental disorders. This suggestion is 
supported by our finding with regards to severe psoriasis and age at inflammatory disorder 
diagnosis. A method of analysis that did not allow for matching might give slightly wider CIs 
and larger p values than a matched analysis.47 Sensitivity analyses that adjusting for matching 
validated the study main findings. We cannot exclude the possibility that the comparison 
group included patients diagnosed with other less common inflammatory disorders (e.g. 
bullous skin diseases, Sjogren syndrome). This concern may have attenuated the true risk of 
depression or anxiety within chronic inflammatory disorders. The study primary aim was to 
model initial inflammatory disorder status (e.g. psoriasis, RA, SLE) and therapy (e.g. 
NSAIDs, corticosteroids), along with patients’ socio-demographic and clinical data to 
patients’ overall risk for future depression or anxiety onset. The analyses, however, did not 
model potential post-diagnosis mediators and moderators for depression or anxiety onset, 
including temporary changes in underlying disease severity, treatment choices, and 
inflammatory responses. These are clinically relevant questions that deserve detailed 
investigation with future prospective studies. The study only differentiated between mild and 
severe psoriasis. The smaller sample of patients within the rest of inflammatory disorders 
precluded a similar classification. This concern also applied to patients with psoriatic arthritis 
that were classified as psoriasis. Given that the definition of severe of psoriasis was based on 
DMARD exposure, however, it is possible that patients with psoriatic arthritis were included 
in the severe psoriasis subgroup. Sensitivity analyses within RA and systemic vasculitis 
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disorders endorsed psoriasis severity results increasing confidence in the robustness of the 
study findings. Future studies with larger IBD, SLE, and AS samples are also required to 
confirm the link between inflammatory disorder severity with study outcomes. Missing data 
on lifestyle covariates can compromise the results of statistical analysis but use of multiple 
imputation and appropriate sensitivity analyses should have mitigated some of this risk. A 
larger proportion of women were diagnosed with AS in this study, which is contrary to other 
studies showing higher AS rates among men.48The study findings about the incidence of 
depression or anxiety may, thus, not be generalisable to the wider AS population. This 
concern was likely caused by the matching of patients and controls on gender, leading to 
intentional non-representativeness. In analytical studies where the aim is to explore exposure-
outcome association (as in this study), however, population representativeness is not 
considered necessary or desirable.49 Richiardi et al.,50 for instance, suggested that non-
representativeness increases the power to assess main effects and effect modification, and 
that valid statistical inferences can be made when adjusting for confounders. Primary care 
patients diagnosed with an inflammatory disorder were at greater risk of new depression and 
anxiety onset compared to matched patients without an inflammatory disorder, a risk that was 
particularly elevated among patients with early onset of chronic inflammatory disorder. These 
findings may reflect either a response to the physical effects of living with a chronic 
inflammatory disorder, or a role for inflammation in the genesis of depression and anxiety. 
The latter hypothesis deserves further attention as it may offer the opportunity for new 
therapeutic approaches to anxiety and depression, but first the question of whether depression 
is a consequence of inflammation or is a reaction to experiencing a chronic illness deserves 
further exploration. Studies evaluating modifiable mediators for depression and anxiety 
incidence across specific inflammatory disorders are also warranted.    
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Table 1*. Participants’ characteristics at baseline assessment. Figures are numbers and percentages unless otherwise specified.   
 RA Psoriasis CD UC SLE Vasculitis AS Total 
 
N 
 
37399 
Mild  
84184 
Severe 
6528 
  
10453 
  
23291 
 
3604 
 
14177 
 
 10363 
Exposed 
180163 
 Unexposed  
358544 
   Follow-up±  4(2,8) 5(2,8) 6(3,9) 4(2,8) 4(2,8) 4(2,8) 4(2,7) 5(2,9) 4(2,8)  4(2,7) 
   Age – M(sd) 60(16) 49(18) 49(16)   46(18) 54(19) 51(16) 65(17) 51(17) 53(18)  53(18) 
   Female 24929(67) 43757(52) 3474(53) 5678(54) 12664(54) 2936(81) 8974(63) 6301(61) 108713(57)  216287(57) 
   Cancer 3164(8) 4319(5) 301(5) 525(5) 1969(8) 261(7) 1673(12) 609(6) 12821(7)  24050(6) 
   CKD 4875(13) 5936(7) 529(8) 895(9) 2836(12) 436(12) 2574(18) 927(9) 19008(10)  28645(8) 
   Diabetes 4224(11) 6349(8) 564(9) 694(7) 2297(10) 259(7) 1934(12) 751(7) 17072(9)  26822(7) 
   CHD 3985(11) 5415(6) 403(6) 688(7) 2345(10) 242(7) 2082(15) 753(7) 15913(8)  25606(7) 
   COPD 2131(6) 2532(3) 200(3) 348(3) 1110(5) 105(3) 935(7) 269(3) 7630(4)  10428(3) 
   Stress 8006(21) 14598(17) 1239(19) 1880(18) 4505(19) 832(23) 2917(21) 2244(22) 36221(19)  57083(15) 
   Hypertension 14177(39) 25138(33) 1993(33) 2402(25) 6945(31) 1063(30) 6472(47) 3071(31) 61261(34)  112226(34) 
   Obesity 9710(29) 18926(27) 1837(34) 1792(20) 4339(21) 714(23) 3284(26) 2122(23) 42724(26)  69536(23) 
   Smoking 27738(76) 55278(69) 4364(70) 7236(82) 17927(80) 2419(69) 11124(81) 7365(74) 133451(73)  262379(76) 
   Alcohol 8060(24) 12930(19) 1103(20) 1826(21) 4195(22) 827(26) 3254(26) 1783(20) 33924(21)  62263(21) 
   AHT 19205(51) 28043(33) 2422(37) 3337(32) 10013(43) 1553(43) 8520(60) 4004(39) 77097(41)  128197(34) 
   Statins 9953(27) 13820(16) 1161(18) 1493(14) 5220(22) 621(17) 4585(32) 1749(17) 38602(20)  64919(17) 
   Hypnotics 5985(16) 9492(11) 934(14) 1366(13) 3361(14) 559(16) 2407(17) 1592(15) 25696(14)  37263(10) 
   NSAIDs 31894(85) 46984(56) 4477(69) 6089(58) 14115(61) 2513(70) 10080(71) 8571(83) 142723(66)  181991(48) 
   Steroids 16467(44) 14390(17) 1893(29) 3499(33) 7022(30) 1287(36) 8444(60) 2490(24) 55492(29)  54104(14) 
Note: * - For ease of presentation some of the covariates data are not presented here. ± figures represent median and interquartile range. M-mean; sd-standard 
deviation; CD- Crohns disease, UC= ulcerative colitis, AS=ankylosing spondylitis, RA= rheumatoid arthritis, SLE=systemic lupus erythematosus. 
AHT=antihypertensive therapy; DMARDs= disease modifying anti-rheumatic drugs; NSADs= non-steroidal anti-inflammatory drugs; CKD= chronic kidney 
disease; COPD= chronic obstructive pulmonary disease; CHD= coronary heart disease.  
26 
 
Table 2. Adjusted hazard ratios (95%confidence interval) for depression and anxiety incidence among persons inflammatory disorders diagnosis 
compared to the matched comparison group.   
   Age at diagnosis   
 
Depression incidence  
Overall sample 
HR(95%CI) 
<40  
HR(95%CI) 
40-49  
HR(95%CI) 
50-59 
HR(95%CI) 
≥60 
HR(95%CI) 
Psoriasis mild 1.30(1.26-1.35) 1.59(1.48-1.71) 1.32(1.20-1.45)  1.01(0.92-1.12)  0.88(0.81-0.95) 
Psoriasis severe 1.71(1.52-1.93) 2.00(1.61-2.48) 1.77(1.39-2.24) 1.21(0.94-1.57) 0.87(0.66-1.13) 
Rheumatoid arthritis 1.38(1.29-1.47) 2.40(2.07-2.79) 1.93(1.68-2.22) 1.40(1.23-1.59) 1.06(0.96-1.17) 
Systemic lupus erythematosus 1.28(1.06-1.56) 1.27(0.91-1.78) 1.53(1.09-2.14) 1.02(0.68-1.54) 0.91(0.65-1.28) 
Ankylosing spondylitis 1.44(1.30-1.60) 1.93(1.59-2.33) 1.62(1.30-2.01) 1.30(1.02-1.65) 1.07(0.87-1.30) 
Systemic vasculitis 1.46(1.31-1.62) 2.52(1.98-3.20) 2.37(1.83-3.09) 1.73(1.37-2.20) 1.23(1.07-1.42) 
Ulcerative colitis 1.39(1.29-1.49) 1.81(1.60-2.05) 1.31(1.09-1.56) 1.44(1.22-1.70) 0.96(0.84-1.09) 
Crohn’s disease 1.47(1.32-1.63) 1.84(1.55-2.19) 1.59(1.26-2.00) 1.28(0.99-1.65) 0.92(0.73-1.14) 
Anxiety incidence       
Psoriasis mild 1.28(1.24-1.33) 1.51(1.40-1.63) 1.08(0.97-1.21) 1.03(0.93-1.15) 0.85(0.78-0.93) 
Psoriasis severe 1.33(1.17-1.50) 1.40(1.10-1.80) 1.31(0.98-1.75) 1.04(0.77-1.41) 0.84(0.63-1.14) 
Rheumatoid arthritis 1.10(1.03-1.18) 1.51(1.26-1.81) 1.20(1.01-1.43) 0.93(0.79-1.09) 0.80(0.71-0.90) 
Systemic lupus erythematosus 1.28(1.06-1.55) 1.25(0.78-1.83) 1.61(1.07-2.42) 1.03(0.63-1.67) 0.78(0.49-1.22) 
Ankylosing spondylitis 1.36(1.23-1.51) 1.54(1.25-1.90) 1.33(1.05-1.70) 1.32(1.03-1.70) 1.08(0.88-1.32) 
Systemic vasculitis 1.19(1.07-1.32) 1.52(1.15-2.02) 1.45(1.04-2.02) 1.24(0.94-1.64) 1.01(0.86-1.18) 
Ulcerative colitis 1.34(1.24-1.44) 1.57(1.35-1.83) 1.21(0.991.48) 0.94(0.76-1.17) 0.86(0.74-1.00) 
Crohn’s disease 1.35(1.21-1.50) 1.24(1.02-1.49) 0.97(0.73-1.28) 1.03(0.76-1.39) 0.78(0.61-1.00) 
HR- hazard rate; CI- confidence interval. Adjusted for age, gender, deprivation, BP, BMI, smoking, alcohol, CHD, stroke, cancer, diabetes, cancer, dementia, 
epilepsy, CKD, liver disease, COPD, sleep disorders, AHT, statins, hypnotics, corticosteroids, NSAIDs, anti-diabetics. 
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Figure 1 Incidence of depression by condition for participants with chronic inflammatory disorders and matched controls.   
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Figure 2. Forest plot displaying random-effects meta-analysis of the influence of specific inflammatory disorders on the incidence of 
multiple depression and anxiety outcomes. CI indicates confidence interval; HR, hazard rate. Basic - adjusted for age and gender. Adjusted – 
adjusted for age, gender, deprivation, BP, BMI, smoking, alcohol, CHD, stroke, cancer, diabetes, cancer, dementia, epilepsy, CKD, liver disease, 
COPD, sleep disorders, AHT, statins, hypnotics, corticosteroids, NSAIDs, anti-diabetics.   
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Figure 3 Forest plot displaying random-effects meta-analysis of the influence of age at inflammatory disorders onset on the incidence of 
multiple depression and anxiety. CI indicates confidence interval; HR, hazard rate. Adjusted for age, gender, deprivation, BP, BMI, smoking, 
alcohol, CHD, stroke, cancer, diabetes, cancer, dementia, epilepsy, CKD, liver disease, COPD, sleep disorders, AHT, statins, hypnotics, 
corticosteroids, NSAIDs, anti-diabetics.  
